These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 34733637)

  • 1. Metabolic disturbances associated with antipsychotic drug treatment in patients with schizophrenia: State-of-the-art and future perspectives.
    Chang SC; Goh KK; Lu ML
    World J Psychiatry; 2021 Oct; 11(10):696-710. PubMed ID: 34733637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia.
    Marteene W; Winckel K; Hollingworth S; Kisely S; Gallagher E; Hahn M; Ebdrup BH; Firth J; Siskind D
    Expert Opin Drug Saf; 2019 Dec; 18(12):1149-1160. PubMed ID: 31564170
    [No Abstract]   [Full Text] [Related]  

  • 5. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment.
    Cooper SJ; Reynolds GP; ; Barnes T; England E; Haddad PM; Heald A; Holt R; Lingford-Hughes A; Osborn D; McGowan O; Patel MX; Paton C; Reid P; Shiers D; Smith J
    J Psychopharmacol; 2016 Aug; 30(8):717-48. PubMed ID: 27147592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
    Mukundan A; Faulkner G; Cohn T; Remington G
    Cochrane Database Syst Rev; 2010 Dec; 2010(12):CD006629. PubMed ID: 21154372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Schizophrenia, diabetes mellitus and antipsychotics].
    Gury C
    Encephale; 2004; 30(4):382-91. PubMed ID: 15538314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management].
    Ruetsch O; Viala A; Bardou H; Martin P; Vacheron MN
    Encephale; 2005; 31(4 Pt 1):507-16. PubMed ID: 16389718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological Interventions for the Prevention of Antipsychotic-Induced Weight Gain in People With Schizophrenia: A Cochrane Systematic Review and Meta-Analysis.
    Agarwal SM; Stogios N; Faulkner GEJ; Hahn M
    Schizophr Bull; 2023 Jul; 49(4):833-835. PubMed ID: 37002951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Adiponectin in the Pathogenesis of Metabolic Disturbances in Patients With Schizophrenia.
    Chen CY; Goh KK; Chen CH; Lu ML
    Front Psychiatry; 2020; 11():605124. PubMed ID: 33551872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic consequences of antipsychotic therapy: preclinical and clinical perspectives on diabetes, diabetic ketoacidosis, and obesity.
    Heal DJ; Gosden J; Jackson HC; Cheetham SC; Smith SL
    Handb Exp Pharmacol; 2012; (212):135-64. PubMed ID: 23129331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic consequences of second-generation antipsychotics in youth: appropriate monitoring and clinical management.
    Krill RA; Kumra S
    Adolesc Health Med Ther; 2014; 5():171-82. PubMed ID: 25298741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment.
    Reynolds GP; McGowan OO
    J Psychopharmacol; 2017 Nov; 31(11):1430-1436. PubMed ID: 28892404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic induced weight gain in schizophrenia:mechanisms and management.
    Rege S
    Aust N Z J Psychiatry; 2008 May; 42(5):369-81. PubMed ID: 18473255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence.
    Dayabandara M; Hanwella R; Ratnatunga S; Seneviratne S; Suraweera C; de Silva VA
    Neuropsychiatr Dis Treat; 2017; 13():2231-2241. PubMed ID: 28883731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Schizophrenia, obesity, and antipsychotic medications: what can we do?
    Citrome L; Vreeland B
    Postgrad Med; 2008 Jul; 120(2):18-33. PubMed ID: 18654065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review.
    Martínez-Ortega JM; Funes-Godoy S; Díaz-Atienza F; Gutiérrez-Rojas L; Pérez-Costillas L; Gurpegui M
    Eur Child Adolesc Psychiatry; 2013 Aug; 22(8):457-79. PubMed ID: 23503976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia.
    Weiden PJ
    J Clin Psychiatry; 2007; 68 Suppl 4():34-9. PubMed ID: 17539698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic complications of schizophrenia and antipsychotic medications--an updated review.
    Yogaratnam J; Biswas N; Vadivel R; Jacob R
    East Asian Arch Psychiatry; 2013 Mar; 23(1):21-8. PubMed ID: 23535629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis.
    Mizuno Y; Suzuki T; Nakagawa A; Yoshida K; Mimura M; Fleischhacker WW; Uchida H
    Schizophr Bull; 2014 Nov; 40(6):1385-403. PubMed ID: 24636967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.